GENEVA, November 10, 2016 /PRNewswire/ -- Cipla and Mylan are the First Companies to Apply for WHO's Prequalification of Dolutegravir The Medicines Patent Pool (MPP) announced today that two of its generic manufacturing partners are the first companies to apply for prequalification of generic dolutegravir (DTG), a new antiretroviral that the MPP licensed from ViiV Healthcare in 2014. Cipla and Mylan have applied to WHO for prequalification of generic versions of the 50 mg tablet of DTG, a necessary step in allowing international procurers such as the Global Fund to Fight AIDS, Tuberculosis and Malaria, UNICEF and UNITAID to purchase and distribute the treatment in developing countries. (Logo: http://photos.prnewswire.com/prnh/20160706/813286 ) "We congratulate our generic partners on achieving this milestone so quickly after signing agreements with the MPP," said Greg Perry, MPP's Executive Director. "We have worked closely with our partners on rapid product development to ensure the availability of generic DTG in low- and middle-income countries shortly after its rollout in high-income nations." Recently recommended as an alternative first-line treatment by the WHO, DTG is considered a significant improvement in antiretroviral therapy. The treatment does not require boosting and has a good barrier to resistance, as well as high efficacy and tolerability at a relatively low dose. As part of a daily regimen, the 50 mg tablet is currently prescribed for patients that have never taken HIV therapy, as well as for the many that have developed resistance to current treatment. "Dolutegravir is an important innovative antiretroviral drug with great ability to reduce viral loads quickly, as well as effectiveness in preventing resistance of the virus," said Sharadd Jain, Head of Cipla Global Access. "This kind of alternative treatment is imperative if we hope to meet international treatment scale-up targets and progress towards the elimination of HIV."